A novel adenoviral vector which mediates hypoxia-inducible gene expression selectively in neurons

Gene Therapy

Volumn 12, Issue 18, 2005, Pages 1369-1376

  Huang, D ^a   Desbois, A ^a   Hou, S T ^a  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

CMVmp; HRE; Human NT2 neurons; Ischemia; Mouse cerebellar granule neurons; Neuron selective and hypoxia inducible adenoviral vector; NRSE

Indexed keywords

ADENOVIRUS VECTOR; HYPOXIA INDUCIBLE FACTOR 1; MESSENGER RNA; PLASMID VECTOR;

ANIMAL CELL; ARTICLE; BRAIN ISCHEMIA; CELL CULTURE; CELL DIFFERENTIATION; CELL STRAIN HEK293; CELL STRAIN HT29; CONTROLLED STUDY; CYTOMEGALOVIRUS; ENZYME ASSAY; EXPRESSION VECTOR; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; GLIA CELL; HUMAN; HUMAN CELL; MITOSIS; NERVE CELL; NERVE CELL LESION; NONHUMAN; OXYGEN CONCENTRATION; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE; SILENCER ELEMENT; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; CELL HYPOXIA; CELL LINE; CELL LINE, TUMOR; CYTOMEGALOVIRUS; GENE EXPRESSION; GENE THERAPY; GENETIC ENGINEERING; GENETIC VECTORS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; NEURONS; PROMOTER REGIONS (GENETICS); RATS; RECOMBINANT FUSION PROTEINS; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTORS; TRANSDUCTION, GENETIC;

ADENOVIRIDAE; ANIMALIA; CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS;

EID: 30744466159     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302538     Document Type: Article

References (55)

1. Cavazzana-Calvo M, Thrasher A, Mavilio F. The future of gene therapy. Nature 2004; 427: 779-781.
2. Feng X, Eide FF, Jiang H, Reder AT. Adeno-associated viral vector-mediated apoe expression in Alzheimer's disease mice: Low CNS immune response, long-term expression, and astrocyte specificity. Front Biosci 2004; 9: 1540-1546.
3. Barkats M et al. Adenovirus in the brain: Recent advances of gene therapy for neurodegenerative diseases. Prog Neurobiol 1998; 55: 333-341.
4. Horellou P, Sabate O, Buc-Caron MH, Mallet J. Adenovirus-mediated gene transfer to the central nervous system for Parkinson's disease. Exp Neurol 1997; 144: 131-138.
5. Benihoud K, Yeh P, Perricaudet M. Adenovirus vectors for gene delivery. Curr Opin Biotechnol 1999; 10: 440-447.
6. Baekelandt V, De Strooper B, Nuttin B, Debyser Z. Gene therapeutic strategies for neurodegenerative diseases. Curr Opin Mol Ther 2000; 2: 540-554.
7. Nadeau I, Kamen A. Production of Adenovirus vector for gene therapy. Biotechnol Adv 2003; 20: 475-489.
8. Masumu M, Hata R. Recent advances in adenovirus-mediated gene therapy for cerebral ischemia. Curr Gene Ther 2003; 3: 43-48.
9. Xu D et al. Attenuation of ischemia-induced cellular and behavioral deficits by X chromosome-linked inhibitor of apoptosis protein overexpression in the rat hippocampus. J Neurosci 1999; 19: 5026-5033.
10. Ferrer I, Planas AM. Signaling of cell death and cell survival following focal cerebral ischemia: Life and death struggle in the penumbra. J Neuropathol Exp Neurol 2003; 62: 329-339.
11. Yenari MA et al. Gene therapy and hypothermia for stroke treatment Ann NY Acad Sci 2003; 993: 54-68.
12. Sakurai M et al. Adenovirus-mediated glial cell line-derived neurotrophic factor gene delivery reduces motor neuron injury after transient spinal cord ischemia in rabbits. J Thorac Cardiovasc Surg 2000; 120: 1148-1157.
13. Abe K, Hayashi T. Expression of the glial cell line-derived neurotrophic factor gene in rat brain after transient MCA occlusion. Brain Res 1997; 776: 230-234.
14. Hou ST, MacManus JP. Molecular mechanisms of cerebral ischemia-induced neuronal death. Int Rev Cytol 2002; 221: 93-148.
15. Krasnykh VN, Douglas JT, van Beusechem VW. Genetic targeting of adenoviral vectors. Mol Ther 2000; 1: 391-405.
16. Ozawa CR et al. Neuroprotective potential of a viral vector system induced by a neurological insult. Proc Natl Acad Sci USA 2000; 97: 9270-9275.
17. Kugler S, Kilic E, Bahr M. Human synapsin 1 gene promoter confers highly neuron-specific long-term transgene expression from an adenoviral vector in the adult rat brain depending on the transduced area. Gene Therapy 2003; 10: 337-347.
18. Li L, Suzuki T, Mori N, Greengard P. Identification of a functional silencer element involved in neuron-specific expression of the synapsin I gene. Proc Natl Acad Sci USA 1993; 90: 1460-1464.
19. Schoch S, Cibelli G, Thiel G. Neuron-specific gene expression of synapsin. I. Major role of a negative regulatory mechanism. J Biol Chem 1996; 271: 3317-3323.
20. Jakobsson J et al. Targeted transgene expression in rat brain using lentiviral vectors. J Neurosci Res 2003; 73: 876-885.
21. Twyman RM, Jones EA. The regulation of neuron-specific gene expression in the mammalian nervous system. J Neurogenet 1995; 10: 67-101.
22. Twyman RM, Jones EA. Sequences in the proximal 5′ flanking region of the rat neuron-specific enolase (NSE) gene are sufficient for cell type-specific reporter gene expression. J Mol Neurosci 1997; 8: 63-73.
23. Gloster A et al. The T alpha 1 alpha-tubulin promoter specifies gene expression as a function of neuronal growth and regeneration in transgenic mice. J Neurosci 1994; 14: 7319-7330.
24. Mori N et al. A cell type-preferred silencer element that controls the neural-specific expression of the SCG10 gene. Neuron 1990; 4: 583-594.
25. Mori N et al. A common silencer element in the SCG10 and type II Na+ channel genes binds a factor present in nonneuronal cells but not in neuronal cells. Neuron 1992; 9: 45-54.
26. Schoenherr CJ, Anderson DJ. The neuron-restrictive silencer factor (NRSF): A coordinate repressor of multiple neuron-specific genes. Science 1995; 267: 1360-1363.
27. Tabuchi A et al. REST4-mediated modulation of REST/NRSF-silencing function during BDNF gene promoter activation. Biochem Biophys Res Commun 2002; 290: 415-420.
28. Wood IC et al. Interaction of the repressor element 1-silencing transcription factor (REST) with target genes. J Mol Biol 2003; 334: 863-874.
29. Wood IC, Roopra A, Buckley NJ. Neural specific expression of the m4 muscarinic acetylcholine receptor gene is mediated by a RE1/NRSE-type silencing element. J Biol Chem 1996; 271: 14221-14225.
30. Navarro V et al. Efficient gene transfer and long-term expression in neurons using a recombinant adenovirus with a neuron-specific promoter. Gene Therapy 1999; 6: 1884-1892.
31. Millecamps S et al. Neuron-restrictive silencer elements mediate neuron specificity of adenoviral gene expression. Nat Biotechnol 1999; 17: 865-869.
32. Binley K et al. An adenoviral vector regulated by hypoxia for the treatment of ischaemic disease and cancer. Gene Therapy 1999; 6: 1721-1727.
33. Binley K, Kan O, White J, Naylor S. Exploiting the hypoxia response. Curr Opin Mol Ther 2003; 5: 650-656.
34. Senrenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-732.
35. Sharp FR, Bergeron M, Bernaudin M. Hypoxia-inducible factor in brain. Adv Exp Med Biol 2001; 502: 273-291.
36. Bergeron M et al. Induction of hypoxia-inducible factor-1 (HIF-1) and its target genes following focal ischaemia in rat brain. Eur J Neurosci 1999; 11: 4159-4170.
37. Semenza GL. HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol 2001; 13: 167-171.
38. 2-regulated gene expression. FASEB J 2002; 16: 1151-1162.
39. Su H, Arakawa-Hoyt J, Kan YW. Adeno-associated viral vector-mediated hypoxia response element-regulated gene expression in mouse ischemic heart model. Proc Natl Acad Sci USA 2002;99: 9480-9485.
40. Shibata T, Giaccia AJ, Brown JM. Hypoxia-inducible regulation of a prodrug-activating enzyme for tumor-specific gene therapy. Neoplasia 2002; 4: 40-48.
41. Post DE, Van Meir EG. Generation of bidirectional hypoxia/HIF-responsive expression vectors to target gene expression to hypoxic cells. Gene Therapy 2001; 8: 1801-1807.
42. Shibata T, Giaccia AJ, Brown JM. Development of a hypoxia-responsive vector for tumor-specific gene therapy. Gene Therapy 2000; 7: 493-498.
43. Garcia-Sanchez R et al. Identification of repressor element 1 in cytochrome P450 genes and their negative regulation by RE1 silencing transcription factor/neuron-restrictive silencer factor. Biochim Biophys Acta 2003; 1620: 39-46.
44. Cao YJ, Shibata T, Rainov NG. Hypoxia-inducible transgene expression in differentiated human NT2N neurons - a cell culture model for gene therapy of postischemic neuronal loss. Gene Therapy 2001; 8: 1357-1362.
45. Cao YJ, Shibata T, Rainov NG. Liposome-mediated transfer of the bcl-2 gene results in neuroprotection after in viva transient focal cerebral ischemia in an animal model. Gene Therapy 2002; 9: 415-419.
46. Koshikawa N, Iyozumi A, Gassmann M, Takenaga K. Constitutive upregulation of hypoxia-inducible factor-1alpha mRNA occurring in highly metastatic lung carcinoma cells leads to vascular endothelial growth factor overexpression upon hypoxic exposure. Oncogene 2003; 22: 6717-6724.
47. Koshikawa N et al. Therapeutic efficacy of the suicide gene driven by the promoter of vascular endothelial growth factor gene against hypoxic tumor cells. Cancer Res 2000; 60: 2936-2941.
48. Onteniente B, Rasika S, Benchoua A, Guegan C. Molecular pathways in cerebral ischemia: Cues to novel therapeutic strategies. Mol Neurobiol 2003; 27: 33-72.
49. Hou ST et al. Activation of the Rb/E2F1 pathway by the nonproliferative p38 MAPK during Fas (APO1/CD95)-mediated neuronal apoptosis. J Biol Chem 2002; 277: 48764-48770.
50. Smith RA, Walker T, Xie X, Hou ST. Involvement of the transcription factor E2F1/Rb in kainic acid-induced death of murine cerebellar granule cells. Brain Res Mol Brain Res 2003; 116: 70-79.
51. Hou ST et al. The transcription factor E2F1 modulates apoptosis of neurons. J Neurochem 2000; 75: 91-100.
52. Hou ST et al. Increases in DNA lesions and the DNA damage indicator Gadd45 following transient cerebral ischemia. Biochem Cell Biol 1997; 75: 383-392.
53. Trojanowski JQ et al. Transfectable and transplantable postmitotic human neurons: A potential 'platform' for gene therapy of nervous system diseases. Exp Neurol 1997; 144: 92-97.
54. Nelson PT. Clonal human (hNT) neuron grafts for stroke therapy: neuropathology in a patient 27 months after implantation. Am J Pathol 2002; 160: 1201-1206.
55. 5 subunits on the membrane of human NT2 neurons. J Mol Neurosci 2004; 24: 217-222.